Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time.

@article{Ioannidis2003RandomisedTC,
  title={Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: biases and evolution over time.},
  author={John P. A. Ioannidis and Anastasia Polycarpou and Christos Ntais and Nicholas Pavlidis},
  journal={European journal of cancer},
  year={2003},
  volume={39 16},
  pages={2278-87}
}
We systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42661 patients), no regimens were compared in >6 studies. Twenty-six trials (10%) found statistically significant differences in survival between the compared arms. Only five reported the randomisation mode, and four reported adequate allocation concealment; nine performed unaccounted interim analyses. Statistical… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2010
View 4 Excerpts
Highly Influenced

Evolution of the randomized controlled trial in oncology over three decades.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2008

Similar Papers

Loading similar papers…